Literature DB >> 21826330

γ-AApeptides bind to RNA by mimicking RNA-binding proteins.

Youhong Niu1, Alisha Jonesy Jones, Haifan Wu, Gabriele Varani, Jianfeng Cai.   

Abstract

The interactions between proteins and RNAs are of vital importance for many cellular processes, including transcription and processing of RNA, translation, and viral infections. Here we report an γ-AApeptide that can mimic HIV-1 Tat protein and bind to TAR RNAs of HIV and BIV with nanomolar affinity, comparable to that of the RNA-binding fragment of Tat (amino acids 49-58). The interaction is resistant to the presence of a large excess of tRNA. With resistance to proteolytic hydrolysis and limitless potential for diversification, γ-AApeptides may emerge as a new class of peptidomimetics to modulate RNA-protein interactions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21826330      PMCID: PMC3814216          DOI: 10.1039/c1ob05738c

Source DB:  PubMed          Journal:  Org Biomol Chem        ISSN: 1477-0520            Impact factor:   3.876


  21 in total

1.  Rational design of inhibitors of HIV-1 TAR RNA through the stabilisation of electrostatic "hot spots".

Authors:  Ben Davis; Mohammad Afshar; Gabriele Varani; Alastair I H Murchie; Jonathan Karn; Georg Lentzen; Martin Drysdale; Justin Bower; Andrew J Potter; Ian D Starkey; Terry Swarbrick; Fareed Aboul-ela
Journal:  J Mol Biol       Date:  2004-02-13       Impact factor: 5.469

2.  Selective binding of TAR RNA by a Tat-derived beta-peptide.

Authors:  Michael A Gelman; Sara Richter; Hong Cao; Naoki Umezawa; Samuel H Gellman; Tariq M Rana
Journal:  Org Lett       Date:  2003-10-02       Impact factor: 6.005

Review 3.  Themes in RNA-protein recognition.

Authors:  D E Draper
Journal:  J Mol Biol       Date:  1999-10-22       Impact factor: 5.469

4.  An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication.

Authors:  F Hamy; E R Felder; G Heizmann; J Lazdins; F Aboul-ela; G Varani; J Karn; T Klimkait
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

5.  Specific recognition of HIV-1 TAR RNA by a D-Tat peptide.

Authors:  I Huq; X Wang; T M Rana
Journal:  Nat Struct Biol       Date:  1997-11

6.  Homonuclear (1)H-NMR assignment and structural characterization of human immunodeficiency virus type 1 Tat Mal protein.

Authors:  C Grégoire; J M Péloponèse; D Esquieu; S Opi; G Campbell; M Solomiac; E Lebrun; J Lebreton; E P Loret
Journal:  Biopolymers       Date:  2001       Impact factor: 2.505

7.  Structure of HIV-1 TAR RNA in the absence of ligands reveals a novel conformation of the trinucleotide bulge.

Authors:  F Aboul-ela; J Karn; G Varani
Journal:  Nucleic Acids Res       Date:  1996-10-15       Impact factor: 16.971

8.  Structural mimicry of retroviral tat proteins by constrained beta-hairpin peptidomimetics: ligands with high affinity and selectivity for viral TAR RNA regulatory elements.

Authors:  Zafiria Athanassiou; Ricardo L A Dias; Kerstin Moehle; Neil Dobson; Gabriele Varani; John A Robinson
Journal:  J Am Chem Soc       Date:  2004-06-09       Impact factor: 15.419

9.  The structure of the human immunodeficiency virus type-1 TAR RNA reveals principles of RNA recognition by Tat protein.

Authors:  F Aboul-ela; J Karn; G Varani
Journal:  J Mol Biol       Date:  1995-10-20       Impact factor: 5.469

10.  Inhibition of both HIV-1 reverse transcription and gene expression by a cyclic peptide that binds the Tat-transactivating response element (TAR) RNA.

Authors:  Matthew S Lalonde; Michael A Lobritz; Annette Ratcliff; Mastooreh Chamanian; Zafiria Athanassiou; Mudit Tyagi; Julian Wong; John A Robinson; Jonathan Karn; Gabriele Varani; Eric J Arts
Journal:  PLoS Pathog       Date:  2011-05-19       Impact factor: 6.823

View more
  18 in total

1.  Design of RNA-targeting macrocyclic peptides.

Authors:  Matthew J Walker; Gabriele Varani
Journal:  Methods Enzymol       Date:  2019-06-13       Impact factor: 1.600

Review 2.  The development of antimicrobial γ-AApeptides.

Authors:  Fengyu She; Olapeju Oyesiku; Peiguang Zhou; Shiming Zhuang; David W Koenig; Jianfeng Cai
Journal:  Future Med Chem       Date:  2016-06-10       Impact factor: 3.808

3.  γ-AApeptides: Design, Structure, and Applications.

Authors:  Yan Shi; Peng Teng; Peng Sang; Fengyu She; Lulu Wei; Jianfeng Cai
Journal:  Acc Chem Res       Date:  2016-02-22       Impact factor: 22.384

Review 4.  Advances in Development of Antimicrobial Peptidomimetics as Potential Drugs.

Authors:  Natalia Molchanova; Paul R Hansen; Henrik Franzyk
Journal:  Molecules       Date:  2017-08-29       Impact factor: 4.411

5.  Identification of γ-AApeptides with potent and broad-spectrum antimicrobial activity.

Authors:  Youhong Niu; Shruti Padhee; Haifan Wu; Ge Bai; Lacey Harrington; Whittney N Burda; Lindsey N Shaw; Chuanhai Cao; Jianfeng Cai
Journal:  Chem Commun (Camb)       Date:  2011-10-03       Impact factor: 6.222

6.  A Macrocyclic Peptide Ligand Binds the Oncogenic MicroRNA-21 Precursor and Suppresses Dicer Processing.

Authors:  Matthew D Shortridge; Matthew J Walker; Tom Pavelitz; Yu Chen; Wen Yang; Gabriele Varani
Journal:  ACS Chem Biol       Date:  2017-05-02       Impact factor: 5.100

Review 7.  Antimicrobial AApeptides.

Authors:  Peng Sang; Yan Shi; Peng Teng; Annie Cao; Hai Xu; Qi Li; Jianfeng Cai
Journal:  Curr Top Med Chem       Date:  2017       Impact factor: 3.295

Review 8.  γ-AApeptides as a New Strategy for Therapeutic Development.

Authors:  Alekhya Nimmagadda; Yan Shi; Jianfeng Cai
Journal:  Curr Med Chem       Date:  2019       Impact factor: 4.530

9.  γ-AApeptides as a New Class of Peptidomimetics.

Authors:  Peng Teng; Yan Shi; Peng Sang; Jianfeng Cai
Journal:  Chemistry       Date:  2016-03-04       Impact factor: 5.236

10.  Studying a Drug-like, RNA-Focused Small Molecule Library Identifies Compounds That Inhibit RNA Toxicity in Myotonic Dystrophy.

Authors:  Suzanne G Rzuczek; Mark R Southern; Matthew D Disney
Journal:  ACS Chem Biol       Date:  2015-09-28       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.